Medic Now

medicnow.com

Medic Now is the UK's leading recruitment agency for ambulance professionals. We enable Paramedics, IHCD Technicians, Emergency Care Assistants and PTS attendants to work on a flexible, locum basis within the industry. We are partnered with several NHS and private organisations throughout the UK; offering a sophisticated staffing solution for our clients with qualified and compliant pre-hospital professional's.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

news image

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

news image

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

news image

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More

MEDTECH

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

news image

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More
news image

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More
news image

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More
news image

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More
news image

MEDTECH

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More